

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/040.659		01/07/2002	Joseph E. Tuck	270/279	2003	
10/040,039		01/0//2002	Joseph E. Fuck		2003	
21890	7590	09/30/2004 .		EXAM	INER	
PROSKA	UER ROS	ELLP	•	DEAK, L	DEAK, LESLIE R	
PATENT I		ENT	•	A DOT LINE	DAREN MARKET	
1585 BRO	1585 BROADWAY			ART UNIT	PAPER NUMBER	
NEW YORK, NY 10036-8299				3762		

DATE MAILED: 09/30/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/040,659	TUCK, JOSEPH E.				
Office Action Summary	Examiner	Art Unit				
	Leslie R. Deak	3762				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
 1) Responsive to communication(s) filed on <u>28 Jules</u> 2a) This action is FINAL. 2b) This 3) Since this application is in condition for alloward closed in accordance with the practice under Exercise 	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4) ⊠ Claim(s) 1-13 and 23-26 is/are pending in the a 4a) Of the above claim(s) is/are withdrav 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1-13 and 23-26 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	vn from consideration.					
Application Papers						
9) ☐ The specification is objected to by the Examine 10) ☑ The drawing(s) filed on 07 January 2002 is/are: Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) ☐ The oath or declaration is objected to by the Ex	a)⊠ accepted or b)⊡ objected drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:					

Art Unit: 3762

DETAILED ACTION

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 1, 4-7, and 10-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,191,183 to Mendelson et al. Mendelson discloses a system and method for delivering a combination of fluids to a patient, including obtaining fluid, combining the fluids in a manifold or container 50, and supplying it to the patient via an infusion line. With regard to applicant's recitation of "purchasing" multiple fluids, all consumable goods are purchased from a source at some point in the acquisition process, therefore rendering the "purchasing" step obvious in the claimed method.
- 3. Claims 2-3, 8, 9, 13, and 23-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,191,183 to Mendelson in view of US 6,649,063 to Brugger et al. Mendelson discloses the method as claimed with the exception of the types and concentrations of solutions provided to the patient. Brugger discloses a system and method for patient treatment that allows a user to custom mix a solution for a patient of one or more of sodium lactate, ringer's, and saline in order to deliver a balanced renal replacement fluid to the patient. Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to use the mixing system disclosed by Mendelson to mix and dispense the renal replacement fluids disclosed by Brugger in

Art Unit: 3762

order to provide a balanced renal replacement therapy to the patient. With regard to applicant's claims drawn to the percent concentration of each solution, it has been held that where the general conditions of a claim are disclosed in the prior art, such as supplying a physiologically effective concentration of renal replacement fluids, are disclosed in the prior art, discovering the optimum or workable ranges, such as the concentration or amount of the supplied fluids, involves only routine skill in the art. See MPEP 2144.05.

Conclusion

Faict et al

- 4. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure:
 - a. US 5,925,011
 - i. System and method for providing sterile fluid mixture to patient in extra corporeal treatment and fluid replacement

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leslie R. Deak whose telephone number is 703-305-0200. The examiner can normally be reached on M-F 7:30-5:00, every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela D. Sykes can be reached on 703-308-5181. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 3762

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

27 September 2004

ANGELA D. SYKES SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700

Cengel. D. Safey